Search Results 831-840 of 18196 for creatine evidence

1. A Study of the Effectiveness and Safety of CTL019 in Adult Patients with Diffuse Large B-Cell Lymphoma - Mayo Clinic

   A serum creatinine of ≤1.5 x Upper Limit of Normal ULN OR ... In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence ...

2. Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL - Mayo Clinic

   Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance > 30 ml/min. ... For patients with evidence of chronic hepatitis B virus (HBV) infection, the ...

3. A Study of the Effect of Vedolizumab in Conjunction with Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis - Mayo Clinic

   Evidence of dysplasia or malignancy on the screening colonoscopy/flexible sigmoidoscopy with biopsy ... creatinine >2 × ULN; Antibiotic use within past 14 ...

4. Vorinostat, Temozolomide, or Bevacizumab in Combination with Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients with Newly Diagnosed High-Grade Glioma - Mayo Clinic

   Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age and/or gender as follows: ... No evidence of significant postoperative ...

5. Neurosurgery - Clinical trials

   Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

6. Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery - Mayo Clinic

   Creatinine ≤ 1.5 X ULN and CrCL ≥ 30 ml/min per Cockcroft Gault formula: (140-Age) x Mass (in kilograms) x (0.85 if Female 72 x Serum Creatinine (in mg/dL) ...

7. XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia - Mayo Clinic

   Prior treatment with an anti-CD38 antibody in last 6 months. 4. Hematopoietic stem cell transplantation within 6 months of enrollment, or evidence of veno ...

8. A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer - Mayo Clinic

   ... evidence of locally recurrent or locally residual (post-resection) disease ... Creatinine ≤ 1.5 X institutional ULN or creatinine clearance ≥ 60 mL/min/1.73m^2 ...

9. Medical Research & Education - Mayo Clinic News Network

   Opioids provide low evidence of pain relief for migraine, large Mayo analysis finds. Joel Streed. July 28, 2021. 20-year Mayo Clinic study suggests return to ...

10. A Study to Evaluate the Effectiveness and Safety of Pemigatinib in Previously-treated, Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) - Mayo Clinic

    Current evidence of clinically significant corneal or retinal disorder as confirmed by ophthalmologic examination. Radiation therapy administered within 2 ...